UT Health Science Center-San Antonio: Mays Cancer Center Studies Help Spur Leukemia Drug's Approval
March 02, 2022
March 02, 2022
SAN ANTONIO, Texas, March 2 (TNSRes) -- The University of Texas Health Science Center at San Antonio issued the following news release:
Investigators at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, played a lead role in gaining U.S. Food and Drug Administration approval of pacritinib to treat the chronic leukemia known as myelofibrosis. The FDA granted accelerated approval of the drug yesterday. The oral capsule is the first therapy specifically a . . .
Investigators at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, played a lead role in gaining U.S. Food and Drug Administration approval of pacritinib to treat the chronic leukemia known as myelofibrosis. The FDA granted accelerated approval of the drug yesterday. The oral capsule is the first therapy specifically a . . .